Ionis says Phase 3 FUSION trial shows ulefnersen improves function and survival in FUS-ALS
Bitget2026/09/22 12:04- Ionis reported positive topline Phase 3 results for ulefnersen in FUS-ALS, supporting a potential first disease-modifying genetic treatment.
- The study showed better outcomes on a combined measure of function and survival versus placebo, supporting a disease-progression impact.
- Safety profile looked favorable, with most adverse events described as mild to moderate.
- Detailed trial results will be presented at a future medical congress, with a peer-reviewed publication planned in coming months.
- Otsuka plans to seek expedited regulatory submission pathways, starting with discussions with the FDA and other global regulators.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia Stock Faces Critical Warning Sign. Is the AI Trade Breaking?
Deutsche Bank estimates the impact of rising interest rates: US major banks face capital pressure, and stock buybacks may collectively hit the brakes.
Deutsche Bank recently released an industry research report focusing on the capital pressure faced by large US banks amid a significant rise in interest rates expected in Q3 2026.
United States Dollar Index weakens further amid correction in US bond yields
AI data center demand surges, Lumentum (LITE.US) optical component orders booked until 2029
As technology companies race to build high-speed AI data centers, Lumentum's (LITE.US) optical components are nearly "sold out," with orders scheduled through early 2029.
Crypto prices
More
